AI Article Synopsis
- The study evaluated the accuracy of various dosimetry protocols for determining the appropriate 131I treatment dose for hyperthyroid patients.
- Forty patients were analyzed, split between those with Graves' disease and those with autonomous thyroid nodules, using tests to estimate maximum uptake and residence time for the radioiodine.
- The results showed that the EANM guidelines provided the best prediction for required treatment activity, while other approaches (ICRP 53 and mono-exponential formula) offered less accurate estimates.
Article Abstract
Background: Aim of the study was to evaluate accuracy of different dosimetry protocols in estimating the required 131I activity to treat hyperthyroid patients.
Materials And Methods: Forty consecutive patients were analysed: twenty-eight Graves' disease; twelve autonomous thyroid nodule (ATN). Maximum-uptake, effective half-time and residence-time were estimated from Radioiodine Uptake Test. Residence-time was estimated using a bi-compartmental model. For 131I activity calculation, algorithms laid down in European Association of Nuclear Medicine (EANM) guidelines, ICRP 53 approach and a mono-exponential formula (ME), were compared with OLINDA/EXM results.
Results: Based on EANM guidelines, activities to be administered were 3% higher in Graves' disease (p = 0.001) and 3% higher in ATN (p = 0.046). Calculated activities using ICRP 53 approach were significantly lower compared to OLINDA/EXM: 33% in Graves' disease; 17% in ATN. Activities recommended by ME, were significantly higher: in Graves' disease 20%; 42% in ATN.
Conclusions: Only EANM algorithm predict quite well, compared to OLINDA/EXM, the required activity to treat hyperthyroid patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5603/NMR.2015.0004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!